Why ImmunityBio Stock Is Skyrocketing Again Today
Key Points
ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials.
It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies.
These developments follow four other significant business updates from earlier this week that have helped the stock double in five days.
- 10 stocks we like better than ImmunityBio ›
Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible slate of good news. This morning, the company announced two bits of great news. First, enrollment for the company's Anktiva therapy exceeded expectations in a trial when treating non-muscle-invasive bladder cancer. This development means ImmunityBio could submit a biologics licensing agreement to the FDA by year's end.
Second, another clinical trial showed that the company's CAR-NK therapy demonstrated 100% disease control in its first four patients with Non-Hodgkin lymphoma. This update could have significant, longer-term implications for ImmunityBio as it develops next-gen therapies beyond its first hit, Anktiva.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
ImmunityBio's incredible week
These fantastic updates occur just:
- one day after management announced preliminary 2025 financials, where Anktiva sales grew over 700%, easily beating Wall Street's expectations
- two days after the Saudi Food and Drug Authority approved Anktiva for use in the country
- three days after the company released positive data on Anktiva treating non-small cell lung cancer
- one week after Anktiva came one step closer to receiving marketing approval across the E.U. from the European Commission
Image source: Getty Images.
The market greeted these six news items with jubilation, as it took a more optimistic view of Anktiva's growing sales, its potentially expanding indications, and ImmunityBio's initial success with longer-term, next-gen therapies. While it is challenging to assign a valuation to ImmunityBio's operations, as it only started generating revenue in 2024, its $5.3 billion market capitalization isn't outrageous given the success it has seen in the last week alone. Armed with roughly $800 million in net cash, ImmunityBio is a well-funded immunotherapy growth stock to watch -- but it could be a volatile ride.
Should you buy stock in ImmunityBio right now?
Before you buy stock in ImmunityBio, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ImmunityBio wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $474,847!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,146,655!*
Now, it’s worth noting Stock Advisor’s total average return is 958% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of January 16, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
